## **MRI-GUIDED RADIATION THERAPY USING** MRI-LINEAR ACCELERATORS

Preface	8 0
1. Introduction	4
1.1 Rationale for this Report.11.2 Scope11.3 Introduction to MRIgRT.1	4 4 4
2. Promising Applications for MRIgRT 1	8
2.1 Limitations of Existing IGRT Strategies12.2 Potential Clinical Advantages of MRIgRT12.3 Limitations of MRIgRT12.4 Existing Clinical Data12.5 Genitourinary Malignancies12.6 Hepatobiliary and Pancreatic Malignancies22.7 Oligometastases22.8 Breast Cancer22.9 Other Clinical Indications22.10 Immobilization, Patient Setup, Repositioning, Patient Comfort, Claustrophobia2	8889923334
3. MRI-Linac Interoperability and Existing MRI-Linac Systems 2	5
3.1 Elekta—Unity Design Considerations23.2 ViewRay—MRIdian Design Considerations23.3 MagnetTx Aurora-RT Design Considerations33.4 Australian MRI-linac Design Considerations3	17 19 10
4. MRIgRT Treatment Planning 3	13
4.1 Treatment Planning System Commissioning.34.2 Absorbed-Dose Calculation.34.3 Treatment Planning Strategies34.4 Deformable Image Registration34.5 MRI-only Planning34.6 When can we Safely Reduce the PTV Margin?3	13 13 13 14 14 36
5. Imaging with an MRI-Linac	37
5.1 Image Quality for MRI Guidance       3         5.2 Technical Requirements of Sequences for MRI Guidance.       4         5.3 Mitigation of Susceptibility Artifacts Due to Metallic Implants       4         5.4 Sequences for Response Monitoring       4	)7  1  3  3
6. Online Adaptive MRIgRT	16
<ul> <li>6.1 Introduction</li></ul>	16 16 17 17 50 52
7. MRIgRT Staffing, Training and Safety	53
7.1 Staff Requirements to Start and Maintain a Program	53 53

7.3 MRI Screening       55         7.4 Radiation Safety       56	
. MRIgRT Commissioning and Dosimetry 57	
8.1 MRI-Linac Commissioning and Ongoing OA	
8.2 Reference Dosimetry Ream Quality Specification 58	
8.3 Desimetry Equinment and Requirements	
8.4 Impact on Ionization Chamber Performance	
8.5 Phantoms	
8.6 Motion/Adaptation	
8.7 Surface and Exit Dosimetry	
8.8 End-to-End Testing	
olo Ena to Ena resting	
. Summary, Recommendations and Future Outlook 61	
9.1 Summary	
9.2 Recommendations	
9.2.1 New MRIgRT Adopters 61	
9.2.2 Experienced MRIgRT Adopters 62	
9.2.3 Hospital Management	
9.2.4 Industry	
9.2.5 Government	
9.2.6 Additional Stakeholders	
9.3. Future Outlook	
9.3.1 Health Care Resource Changes	
9.3.2 Clinical Opportunities	
9.3.3 Technical Advances Needed to Further Improve Patient Outcomes	
0. Acknowledgments	
ppendix A: Table of Resources that Augment this ICRU Report	
ppendix A: Table of Resources that Augment this ICRU Report	
Appendix A: Table of Resources that Augment this ICRU Report       65         Appendix B: Safety Screening Form Examples       66         B.1 Initial MRI-Linac Safety Screening Questionnaire       66	
Appendix A: Table of Resources that Augment this ICRU Report       65         Appendix B: Safety Screening Form Examples       66         B.1 Initial MRI-Linac Safety Screening Questionnaire       66         B.2 Daily MRI-Linac Safety Screening Questionnaire.       66	
Appendix A: Table of Resources that Augment this ICRU Report	
Appendix A: Table of Resources that Augment this ICRU Report       65         Appendix B: Safety Screening Form Examples       66         B.1 Initial MRI-Linac Safety Screening Questionnaire       66         B.2 Daily MRI-Linac Safety Screening Questionnaire.       66         Sppendix C: Clinical Examples.       67         C 1 Prostate Concer       67	
Appendix A: Table of Resources that Augment this ICRU Report       65         Appendix B: Safety Screening Form Examples       66         B.1 Initial MRI-Linac Safety Screening Questionnaire       66         B.2 Daily MRI-Linac Safety Screening Questionnaire       66         Appendix C: Clinical Examples       67         C.1 Prostate Cancer       67	
Appendix A: Table of Resources that Augment this ICRU Report       65         Appendix B: Safety Screening Form Examples       66         B.1 Initial MRI-Linac Safety Screening Questionnaire       66         B.2 Daily MRI-Linac Safety Screening Questionnaire       66         Sppendix C: Clinical Examples       67         C.1 Prostate Cancer       67         C.1.1 Clinical Scenario       67         C.1.2 Treatment Intent       67	
Appendix A: Table of Resources that Augment this ICRU Report       65         Appendix B: Safety Screening Form Examples       66         B.1 Initial MRI-Linac Safety Screening Questionnaire       66         B.2 Daily MRI-Linac Safety Screening Questionnaire.       66         Appendix C: Clinical Examples.       67         C.1 Prostate Cancer.       67         C.1.1 Clinical Scenario.       67         C.1.2 Treatment Intent.       67         C.1.3 Patient Positioning and Image Acquisition       68	
Appendix A: Table of Resources that Augment this ICRU Report       65         Appendix B: Safety Screening Form Examples       66         B.1 Initial MRI-Linac Safety Screening Questionnaire       66         B.2 Daily MRI-Linac Safety Screening Questionnaire       66         Appendix C: Clinical Examples       67         C.1 Prostate Cancer       67         C.1.1 Clinical Scenario.       67         C.1.2 Treatment Intent.       67         C.1.3 Patient Positioning and Image Acquisition       68	
Appendix A: Table of Resources that Augment this ICRU Report       65         Appendix B: Safety Screening Form Examples       66         B.1 Initial MRI-Linac Safety Screening Questionnaire       66         B.2 Daily MRI-Linac Safety Screening Questionnaire       66         Sppendix C: Clinical Examples       67         C.1 Prostate Cancer       67         C.1.1 Clinical Scenario.       67         C.1.2 Treatment Intent.       67         C.1.3 Patient Positioning and Image Acquisition       68         C.1.4 Target Volumes       68	
sppendix A: Table of Resources that Augment this ICRU Report       65         sppendix B: Safety Screening Form Examples       66         B.1 Initial MRI-Linac Safety Screening Questionnaire       66         B.2 Daily MRI-Linac Safety Screening Questionnaire       66         sppendix C: Clinical Examples.       67         C.1 Prostate Cancer.       67         C.1.1 Clinical Scenario.       67         C.1.2 Treatment Intent.       67         C.1.3 Patient Positioning and Image Acquisition       68         C.1.4 Target Volumes       68         C.1.5 Organs at Risk       68	
xppendix A: Table of Resources that Augment this ICRU Report       65         xppendix B: Safety Screening Form Examples       66         B.1 Initial MRI-Linac Safety Screening Questionnaire       66         B.2 Daily MRI-Linac Safety Screening Questionnaire       66         sppendix C: Clinical Examples       67         C.1 Prostate Cancer       67         C.1.1 Clinical Scenario.       67         C.1.2 Treatment Intent.       67         C.1.4 Target Volumes       68         C.1.5 Organs at Risk       68         C.1.6 Planning Aim       68         C.1.7 Treatment Planning       68	
xppendix A: Table of Resources that Augment this ICRU Report       65         xppendix B: Safety Screening Form Examples.       66         B.1 Initial MRI-Linac Safety Screening Questionnaire.       66         B.2 Daily MRI-Linac Safety Screening Questionnaire.       66         sppendix C: Clinical Examples.       67         C.1 Prostate Cancer.       67         C.1.1 Clinical Scenario.       67         C.1.2 Treatment Intent.       67         C.1.3 Patient Positioning and Image Acquisition       68         C.1.5 Organs at Risk       68         C.1.6 Planning Aim       68         C.1.7 Treatment Delivery and Daily Adaptation       68	
appendix A: Table of Resources that Augment this ICRU Report       65         appendix B: Safety Screening Form Examples       66         B.1 Initial MRI-Linac Safety Screening Questionnaire       66         B.2 Daily MRI-Linac Safety Screening Questionnaire       66         sppendix C: Clinical Examples       67         C.1 Prostate Cancer       67         C.1.1 Clinical Scenario.       67         C.1.2 Treatment Intent.       67         C.1.3 Patient Positioning and Image Acquisition       68         C.1.4 Target Volumes       68         C.1.5 Organs at Risk       68         C.1.7 Treatment Planning       68         C.1.8 Treatment Delivery and Daily Adaptation       68         C.1.9 Treatment Outcome       71	
appendix A: Table of Resources that Augment this ICRU Report       65         appendix B: Safety Screening Form Examples.       66         B.1 Initial MRI-Linac Safety Screening Questionnaire       66         B.2 Daily MRI-Linac Safety Screening Questionnaire.       66         sppendix C: Clinical Examples.       67         C.1 Prostate Cancer.       67         C.1.1 Clinical Scenario.       67         C.1.2 Treatment Intent.       67         C.1.3 Patient Positioning and Image Acquisition       68         C.1.4 Target Volumes.       68         C.1.5 Organs at Risk       68         C.1.7 Treatment Planning       68         C.1.8 Treatment Delivery and Daily Adaptation.       68         C.1.9 Treatment Outcome       71	
Appendix A: Table of Resources that Augment this ICRU Report       65         Appendix B: Safety Screening Form Examples.       66         B.1 Initial MRI-Linac Safety Screening Questionnaire.       66         B.2 Daily MRI-Linac Safety Screening Questionnaire.       66         Sppendix C: Clinical Examples.       67         C.1 Prostate Cancer.       67         C.1.1 Clinical Scenario.       67         C.1.2 Treatment Intent.       67         C.1.3 Patient Positioning and Image Acquisition       68         C.1.4 Target Volumes.       68         C.1.5 Organs at Risk       68         C.1.7 Treatment Planning       68         C.1.8 Treatment Delivery and Daily Adaptation.       68         C.1.9 Treatment Outcome       71         C.2.1 Clinical Scenario.       71	
appendix A: Table of Resources that Augment this ICRU Report       65         appendix B: Safety Screening Form Examples       66         B.1 Initial MRI-Linac Safety Screening Questionnaire       66         B.2 Daily MRI-Linac Safety Screening Questionnaire       66         sppendix C: Clinical Examples       67         C.1 Prostate Cancer.       67         C.1.1 Clinical Scenario.       67         C.1.2 Treatment Intent.       67         C.1.3 Patient Positioning and Image Acquisition       68         C.1.4 Target Volumes       68         C.1.5 Organs at Risk       68         C.1.7 Treatment Planning       68         C.1.8 Treatment Delivery and Daily Adaptation.       68         C.1.9 Treatment Outcome       71         C.2.1 Clinical Scenario.       71         C.2.1 Clinical Scenario.       71	
appendix A: Table of Resources that Augment this ICRU Report       65         appendix B: Safety Screening Form Examples.       66         B.1 Initial MRI-Linac Safety Screening Questionnaire       66         B.2 Daily MRI-Linac Safety Screening Questionnaire       66         spendix C: Clinical Examples.       67         C.1 Prostate Cancer.       67         C.1.1 Clinical Scenario.       67         C.1.2 Treatment Intent.       67         C.1.3 Patient Positioning and Image Acquisition       68         C.1.4 Target Volumes       68         C.1.5 Organs at Risk       68         C.1.6 Planning Aim       68         C.1.7 Treatment Planning       68         C.1.8 Treatment Delivery and Daily Adaptation       68         C.1.9 Treatment Outcome       71         C.2.1 Clinical Scenario.       71         C.2.2 Treatment Intent.       71         C.2.3 Patient Positioning and Image Acquisition       71	
Appendix A: Table of Resources that Augment this ICRU Report       65         Appendix B: Safety Screening Form Examples.       66         B.1 Initial MRI-Linac Safety Screening Questionnaire       66         B.2 Daily MRI-Linac Safety Screening Questionnaire       66         sppendix C: Clinical Examples.       67         C.1 Prostate Cancer.       67         C.1 Prostate Cancer.       67         C.1.2 Treatment Intent.       67         C.1.3 Patient Positioning and Image Acquisition       68         C.1.4 Target Volumes.       68         C.1.5 Organs at Risk       68         C.1.6 Planning Aim       68         C.1.7 Treatment Delivery and Daily Adaptation       68         C.1.8 Treatment Delivery and Daily Adaptation       68         C.1.9 Treatment Intent.       71         C.2. Oligometastatic Progression in the Upper Abdomen       71         C.2.1 Clinical Scenario.       71         C.2.2 Treatment Intent.       71         C.2.3 Patient Positioning and Image Acquisition       71         C.2.4 Tareet Volumes.       71	
Appendix A: Table of Resources that Augment this ICRU Report       65         Appendix B: Safety Screening Form Examples.       66         B.1 Initial MRI-Linac Safety Screening Questionnaire       66         B.2 Daily MRI-Linac Safety Screening Questionnaire.       66         sppendix C: Clinical Examples.       67         C.1 Prostate Cancer.       67         C.1 Prostate Cancer.       67         C.1.2 Treatment Intent.       67         C.1.3 Patient Positioning and Image Acquisition       68         C.1.4 Target Volumes.       68         C.1.5 Organs at Risk       68         C.1.8 Treatment Planning       68         C.1.9 Treatment Delivery and Daily Adaptation.       68         C.1.9 Treatment Delivery and Daily Adaptation.       61         C.2. Oligometastatic Progression in the Upper Abdomen       71         C.2.1 Clinical Scenario.       71         C.2.2 Treatment Intent.       71         C.2.3 Patient Positioning and Image Acquisition       71         C.2.4 Target Volumes.       71         C.2.5 Organs at Risk       71	
appendix A: Table of Resources that Augment this ICRU Report       65         appendix B: Safety Screening Form Examples.       66         B.1 Initial MRI-Linac Safety Screening Questionnaire.       66         B.2 Daily MRI-Linac Safety Screening Questionnaire.       66         B.2 Daily MRI-Linac Safety Screening Questionnaire.       66         sppendix C: Clinical Examples.       67         C.1 Prostate Cancer.       67         C.1.1 Clinical Scenario.       67         C.1.2 Treatment Intent.       67         C.1.3 Patient Positioning and Image Acquisition       68         C.1.4 Target Volumes.       68         C.1.5 Organs at Risk       68         C.1.6 Planning Aim       68         C.1.7 Treatment Delivery and Daily Adaptation.       68         C.1.9 Treatment Delivery and Daily Adaptation.       71         C.2.1 Clinical Scenario.       71         C.2.1 Clinical Scenario.       71         C.2.2 Treatment Intent.       71         C.2.3 Patient Positioning and Image Acquisition       71         C.2.4 Target Volumes.       71         C.2.5 Organs at Risk       71         C.2.6 Planning Aim       71	
xppendix A: Table of Resources that Augment this ICRU Report       65         xppendix B: Safety Screening Form Examples       66         B.1 Initial MRI-Linac Safety Screening Questionnaire       66         B.2 Daily MRI-Linac Safety Screening Questionnaire       66         sppendix C: Clinical Examples       67         C.1 Prostate Cancer       67         C.1.1 Clinical Scenario.       67         C.1.2 Treatment Intent.       67         C.1.3 Patient Positioning and Image Acquisition       68         C.1.4 Target Volumes.       68         C.1.5 Organs at Risk       68         C.1.8 Treatment Delivery and Daily Adaptation       68         C.1.9 Treatment Outcome       71         C.2.1 Clinical Scenario.       71         C.2.2 Treatment Intent.       71         C.2.3 Patient Positioning and Image Acquisition       71         C.2.4 Target Volumes.       71         C.2.5 Organs at Risk       71         C.2.6 Planning Aim       71         C.2.7 Treatment Intent.       71         C.2.6 Organs at Risk       71         C.2.7 Treatment Intent.       71         C.2.6 Organs at Risk       71         C.2.7 Treatment Intent.       71         C.2.6 Planning Aim	
xppendix A: Table of Resources that Augment this ICRU Report       65         xppendix B: Safety Screening Form Examples       66         B.1 Initial MRI-Linac Safety Screening Questionnaire       66         B.2 Daily MRI-Linac Safety Screening Questionnaire       66         sppendix C: Clinical Examples       67         C.1 Prostate Cancer.       67         C.1.1 Clinical Scenario.       67         C.1.2 Treatment Intent.       67         C.1.3 Patient Positioning and Image Acquisition       68         C.1.4 Target Volumes.       68         C.1.5 Organs at Risk       68         C.1.6 Planning Aim       68         C.1.7 Treatment Delivery and Daily Adaptation       68         C.1.8 Treatment Delivery and Daily Adaptation       71         C.2.1 Clinical Scenario.       71         C.2.2 Treatment Intent.       71         C.2.3 Patient Positioning and Image Acquisition       71         C.2.4 Target Volumes.       71         C.2.5 Organs at Risk       71         C.2.4 Target Volumes.       71         C.2.5 Organs at Risk       71         C.2.6 Planning Aim       71         C.2.7 Treatment Intent.       71         C.2.8 Treatment Planning       71         C.2.6	

C.3. Recurrent Oligometastatic Disease in the Pelvis.	73
C.3.1 Clinical Scenario	74
C.3.2 Treatment Intent	74
C.3.3 Patient Positioning and Image Acquisition	74
C.3.4 Target Volumes	
C.3.5 Organs at Risk	
C.3.6 Treatment Planning	74
C.3.7 Treatment Delivery and Daily Adaptation	75
C.3.8 Treatment Outcome	
C.4. Partial Breast Radiotherapy	
C.4.1 Clinical Scenario.	
C.4.2 Treatment Intent.	
C.4.3 Patient Positioning and Image Acquisition	76
C.4.4 Target Volumes	77
C.4.5 Organs at Risk	77
C.4.6 Planning Aim	77
C.4.7 Treatment Planning	77
C.4.8 Treatment Delivery and Daily Adaptation	77
C.4.9 Treatment Outcome	78
C.5. Multi-target Oligometastatic Case	78
C.5.1 Clinical Scenario.	78
C.5.2 Treatment Intent.	78
C.5.3 Patient Positioning and Image Acquisition	79
C.5.4 Target Volumes	79
C.5.5 Organs at Risk	79
C.5.6 Planning Aim	80
C.5.7 Treatment Planning	80
C.5.8 Treatment Delivery and Adaptation	80
C.5.9 Treatment Outcome	80
C.6. Head and Neck Cancer	80
C.6.1 Clinical Scenario.	80
C.6.2 Treatment Intent.	<b>8</b> 1
C.6.3 Patient Positioning and Image Acquisition	<b>8</b> 1
C.6.4 Target Volumes	82
C.6.5 Organs at Risk	82
C.6.6 Planning Aim	82
C.6.7 Treatment Planning	82
C.6.8 Treatment Delivery, Serial Adaptation, and Quantitative Imaging.	83
C.6.9 Treatment Outcome	86
C.7. Ventricular Tachycardia	87
C.7.1 Clinical Scenario.	8
C.7.2 Treatment Intent.	88
C.7.3 Patient Positioning and Image Acquisition	8
C.7.4 Target Volumes	89
C.7.5 Organs at Risk	89
C.7.6 Planning Aim	89
C.7.7 Treatment Planning	89
C.7.8 Treatment Delivery.	8
C.7.9 Treatment Outcome	9
	•
References	9